Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

132.26 -4.64 (-3.39%)
Streaming Delayed Price Updated: 3:21 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,696,397
Open 133.60
Bid (Size) 132.25 (3)
Ask (Size) 132.28 (2)
Prev. Close 136.90
Today's Range 131.80 - 135.16
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.34%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
No need to break the bank to get in on these excellent companies. 
Via The Motley Fool

Performance

YTD
+29.53%
+29.53%
1 Month
-2.21%
-2.21%
3 Month
-5.78%
-5.78%
6 Month
-0.47%
-0.47%
1 Year
+41.75%
+41.75%

More News

Read More
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
Via Benzinga
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Via Benzinga
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
Via The Motley Fool
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
Via Benzinga
Novo Nordisk Unusual Options Activity
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Via Benzinga
Exposures Product Safety
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Via The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Via Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Via The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Via The Motley Fool
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.